WO2015077977A1 - 一种用于治疗溃疡性结肠炎的中药组合物及其制备方法 - Google Patents

一种用于治疗溃疡性结肠炎的中药组合物及其制备方法 Download PDF

Info

Publication number
WO2015077977A1
WO2015077977A1 PCT/CN2013/088143 CN2013088143W WO2015077977A1 WO 2015077977 A1 WO2015077977 A1 WO 2015077977A1 CN 2013088143 W CN2013088143 W CN 2013088143W WO 2015077977 A1 WO2015077977 A1 WO 2015077977A1
Authority
WO
WIPO (PCT)
Prior art keywords
weight
parts
licorice
chinese medicine
traditional chinese
Prior art date
Application number
PCT/CN2013/088143
Other languages
English (en)
French (fr)
Inventor
李军祥
Original Assignee
北京中医药大学东方医院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 北京中医药大学东方医院 filed Critical 北京中医药大学东方医院
Priority to PCT/CN2013/088143 priority Critical patent/WO2015077977A1/zh
Priority to CN201380080916.6A priority patent/CN105722521B/zh
Publication of WO2015077977A1 publication Critical patent/WO2015077977A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/25Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258Panax (ginseng)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/31Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A61K36/315Isatis, e.g. Dyer's woad
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484Glycyrrhiza (licorice)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/489Sophora, e.g. necklacepod or mamani
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/71Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/718Coptis (goldthread)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/73Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/739Sanguisorba (burnet)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/906Zingiberaceae (Ginger family)
    • A61K36/9068Zingiber, e.g. garden ginger
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Definitions

  • the present invention relates to the field of traditional Chinese medicine preparations, and in particular to a traditional Chinese medicine composition for treating ulcerative colitis and a preparation method thereof.
  • Ulcerative colitis is a chronic non-specific inflammatory disease of the colon and rectum that is not well understood. The lesion is confined to the large intestine mucosa and submucosa. Most of the lesions are located in the sigmoid colon and rectum, but also extend to the descending colon, or even the entire colon. The course of the disease is long and often recurrent. It can occur at any age. It is more common in books 20-40 years old. There is no significant difference in the incidence of men and women. It is the digestive medicine. Diseases, Chinese medicine belong to the category of "intestinal fistula" and "dysentery". The clinical manifestations of ulcerative colitis can be in many forms.
  • Mucus pus and blood is an important manifestation of the active period of the disease.
  • Other symptoms include abdominal pain, nausea, vomiting, weight loss, urgency, etc., sometimes accompanied by peripheral arthritis, scleral outer layer.
  • Intestinal manifestations such as inflammation, oral ulcers and skin lesions, moderate and severe patients with active body, fever, anemia and other systemic manifestations.
  • the disease manifests as chronic, low-grade, with acute onset in a small number of patients (about 15%), and occasionally an acute outbreak.
  • These patients present with frequent bloody stools, up to 30 times per day, and high fever and abdominal pain.
  • the signs are directly related to the disease and clinical manifestations. Patients often have weight loss and pale complexion. During the abdominal examination of the disease, the colon often has tenderness.
  • aminosalicylic drugs are currently commonly used in clinical treatment for mild to moderate ulceration.
  • Drugs for ulcerative colitis including salicyl sulfasalazine (SASP), 5-aminosalicylic acid (5-ASA), etc.
  • SASP salicyl sulfasalazine
  • 5-ASA 5-aminosalicylic acid
  • Glucocorticoids such as prednisolone, dexamethasone, hydrocortisone, etc., have only good effects on short-term relief symptoms, some drugs have low bioavailability, many intestinal defects, and long-term defects. Taking hormonal drugs may aggravate or induce infection, and may cause delayed or vaginal adverse reactions related to the cumulative amount.
  • Liver stagnation and spleen deficiency type is chronic recurrent or persistent type
  • abdominal pain, diarrhea, postprandial pain reduction, chest tightness, bloating and other symptoms Yishu liver and spleen, qi and stomach, with pain and diarrhea, phlegm and blood stasis
  • spleen and stomach weak chronic persistent Patients, when they have bowel movements, have sputum, sputum, mucus or water valleys, pale complexion, weak limbs, pale tongue, white veins, weak pulse and other symptoms, should be spleen and qi, and stomach Wet, with Shenqi Baizhu Powder as the main prescription
  • spleen and kidney yang deficiency type is a chronic persistent type patient, with five
  • the technical problem to be solved by the present invention is that the prior art medicine has poor effect on treating ulcerative colitis, has high recurrence rate, and has obvious side effects, thereby providing a good effect for treating ulcerative colitis and low recurrence rate. And a traditional Chinese medicine composition having no obvious side effects and a preparation method thereof.
  • the present invention provides a method for treating ulcerative colitis.
  • the pharmaceutical composition the composition of the raw material of the composition is: 7-11 parts by weight of Rhizoma Coptidis, 7-11 parts by weight of gun ginger, 7-11 parts by weight of Sophora flavescens, 4-8 parts by weight of Sanqi, 4-11 weight of Qinglan A portion, 4-8 parts by weight of woody notes, 7-11 parts by weight of mantle charcoal, and 1-5 parts by weight of licorice.
  • the traditional Chinese medicine composition for treating ulcerative colitis the composition of the raw material of the composition is: 9 parts by weight of Rhizoma Coptidis, 9 parts by weight of gun ginger, 9 parts by weight of Sophora flavescens, 6 parts by weight of Panax notoginseng, Qingyan 9 Parts by weight, wood parts, 6 parts by weight, earthworm charcoal, 9 parts by weight, and licorice, 3 parts by weight; or
  • Rhizoma Coptidis 8 parts by weight of Rhizoma Coptidis, 10 parts by weight of gun ginger, 8 parts by weight of Sophora flavescens, 7 parts by weight of ginseng, 5 parts by weight of barley, 7 parts by weight of woody notes, 10 parts by weight of earthworm charcoal and 4 parts by weight of licorice; or
  • Rhizoma Coptidis 8 parts by weight of Rhizoma Coptidis, 7 parts by weight of gun ginger, 7 parts by weight of Sophora flavescens, 6 parts by weight of ginseng, 11 parts by weight of eucalyptus, 4 parts by weight of woody, 11 parts by weight of medlar and 4 parts by weight of licorice; or
  • the traditional Chinese medicine composition for treating ulcerative colitis which is added to a conventional excipient according to a conventional process to prepare a clinically acceptable dosage form of granules, capsules, pills, suppositories and the like.
  • a method of preparing the above traditional Chinese medicine composition for treating ulcerative colitis comprising the following steps:
  • the method includes the following steps:
  • the selected parts by weight take the scutellaria, gun ginger, Sophora flavescens, Panax notoginseng, barley, woody, earthworm charcoal and licorice grass and mix them into a coarse powder, add 8 times the weight of the drug to 60% ethanol, and after immersing for 30 hours, The liquid is heated to maintain the temperature of the liquid solution at 35 ° C, forced circulation for 3.5 hours, filtered, and the alcohol extract is added, and conventional excipients are added, and clinically acceptable granules, capsules, pills, and suppositories are prepared according to a conventional process.
  • the invention also discloses a traditional Chinese medicine composition for treating ulcerative colitis which is prepared by the above preparation method, and the use of the above traditional Chinese medicine composition for preparing a medicament for treating ulcerative colitis.
  • the applicant believes that the clinical symptoms of patients with ulcerative colitis are diarrhea, mucus pus and bloody stools, abdominal pain, and urgency after the main disease.
  • the pathogenesis is spleen-deficiency
  • the intestinal damp heat is the standard
  • the key to the pathogenesis is cold and heat.
  • the traditional Chinese medicine composition of the invention It consists of berberine, gun ginger, Kushen, Sanqi, Qinglan, Muxiang, Dijiao and Licorice, Fangzhong Huanglian, Sophora flavescens, Qinglan, Mantle charcoal bitter cold into blood, can clear the intestines to stop bleeding; It can warm the spleen and stop diarrhea, and can also make the chilling of various drugs such as berberine, and regulate the cold and heat; Sanqi phlegm and blood stasis, wood scented smooth air machine, all kinds of medicines can get clear and intestines damp heat, warm and spleen, calming cold and heat , the effect of phlegm and blood stasis, thereby achieving the purpose of reducing the pain of the
  • the traditional Chinese medicine composition for treating ulcerative colitis according to the present invention has a good therapeutic effect, and has the effects of clearing intestinal moist heat, warming the spleen, regulating the cold and heat, and relieving blood stasis to relieve the pain of the disease and improve Quality of life, the purpose of extending the time to live;
  • the traditional Chinese medicine composition for treating ulcerative colitis according to the present invention has no significant difference in the disease activity index (DAI) level compared with the existing drug sulfasalazine enteric-coated tablet.
  • DAI disease activity index
  • the traditional Chinese medicine composition of the invention is used In the experimental colitis rats, the colon adhered to the surrounding tissues lightly, and there was no reddish-brown inflammatory pseudomembrane on the surface of the colon, which was relieved by congestion and edema, and the colonic mucosal injury index of the existing drug sulfasalazine enteric-coated tablets ( There was no significant difference in the level of conlonic mucosa damage index, CMDI).
  • the histopathological scores of the colonies in each dose group of the present invention were significantly lower than those in the model group P ⁇ 0.05, and the degree of inflammatory cell infiltration in the QCWZD high and QCWZD middle dose groups of the present invention. It was significantly lower than the model group; the serum levels of IL-6 and TNF- ⁇ in the rats were significantly lower than those in the model group (P ⁇ 0.05), and there was no significant difference with the level of the blank group;
  • a method for preparing a traditional Chinese medicine composition for treating ulcerative colitis by which a clinically acceptable composition of a traditional Chinese medicine such as a granule, a capsule, a pill, a suppository or the like is obtained, which is more convenient Take, store, have good stability and high safety.
  • a traditional Chinese medicine such as a granule, a capsule, a pill, a suppository or the like
  • the use of the present invention in the treatment of ulcerative colitis is better illustrated by the basic test examples below.
  • the traditional Chinese medicine composition of the present invention proved that the effect of the traditional Chinese medicine composition of the present invention for treating ulcerative colitis was remarkable as compared with the control group.
  • Experimental animals healthy SD rats, 35 males, weighing 200 ⁇ 20 g, grade SPF.
  • Experimental drug The drug of the test group is the traditional Chinese medicine composition prepared in the first embodiment, and the dosage of each dose is 1200 mg/kg, the crude drug amount is 600 mg/kg, and the crude drug amount is 300 mg/kg, which is divided into QCWZD high, QCWZD.
  • Medium and QCWZD low-dose test group The control group was SASP group, that is, the drug was sulfasalazine enteric-coated tablet, and the dose per dose was 400 mg/kg.
  • Both the blank group and the model group were given normal saline of lOml/kg mouse body weight; the control group was administered with a dose of 400 mg/kg of rat body weight; the QCWZD high, medium and low dose group was the traditional Chinese medicine prepared in Example 1 of the present invention.
  • the composition was divided into high, medium and low dose groups according to the dosage to be administered.
  • the doses of each dose were 1200 mg/kg of the body weight of the crude drug, 600 mg/kg of the body weight of the crude drug, and 300 mg/kg of the body weight of the drug.
  • Each administration group was intragastrically administered once a day for 10 days.
  • the rats in the model group developed diarrhea, which was yellow loose stool, semi-dilute stool and even bloody stool. At this time, the rat hair color was tarnished, the activity was poor, the reaction was slow and lazy, and the DAI reached the maximum on the third day.
  • the rats in each medication group improved their spirits, the color of the coat became lustrous, the appetite increased, the activity gradually increased, the stool became normal, and the DAI decreased significantly.
  • the rats in the blank group did not have the above changes in spirit, activity, and coat color, as shown in Table 1.
  • the DAI of the model group was still significantly higher than that of the blank group (P ⁇ 0.05).
  • the SASP group and the various dose groups of the present invention showed a significant decrease compared with the model group ( ⁇ 0.05).
  • the QCWZD high school of the present invention The level of DAI in the low-dose group was not significantly different from that in the salazosulfapyridine (SASP) group (P>0.05), as shown in Table 2.
  • QCWZD high dose 1 group 0.00 ⁇ 0 ⁇ 00 1.37 ⁇ 0 ⁇ 56 0.57 ⁇ 0 ⁇ 32 a 0.50 ⁇ 0.25 ad
  • QCWZD medium 1 group 0.00 ⁇ 0 ⁇ 00 2.10 ⁇ 0 ⁇ 47 0.53 ⁇ 0 ⁇ 61 a 0.45 ⁇ 0.47 ad
  • QCWZD low dose 1 group 0.00 ⁇ 0 ⁇ 00 2.13 ⁇ 0 ⁇ 45 0.47 ⁇ 0.39 a 0.46 ⁇ 0.31 ad
  • the model group showed macroscopic colonic mucosal erosion, deep ulcer and large area, obvious intestinal contents embedded in the ulcer, difficult to wash; visible edema, hyperemia, colon surface covered with reddish-brown inflammatory pseudomembrane; colon lesion intestine The cavity is dilated and deformed; the diseased colon adheres to the surrounding tissue clearly and is not easy to separate. The adhesion of the colon to the surrounding tissues was lighter in each drug group, and there was no reddish-brown inflammatory pseudomembrane on the surface of the colon. The congestion and edema were alleviated, and the ulcer was healed.
  • CMDI colonic mucosa damage index
  • QCWZD Medium 1 Group 6 2.25 ⁇ 0.89 gh 0.45 ⁇ 0.27 gh
  • QCWZD low dose 1 group 6 3.00 ⁇ 0 ⁇ 00 0.46 ⁇ 0.31
  • Rat Colon HS mucosal hyperemia and edema were observed under light microscope, and a large number of inflammatory cells infiltrated, mainly lymphocytes and neutrophils. The depth of the lesion reached the submucosa, muscle layer and even the serosa layer; the goblet cells were significantly reduced, ulcer The surrounding part of the gland is dilated, the gland is disordered, the glandular epithelial cells are slightly hyperplasia, and some are associated with atypical hyperplasia of the gland, and inflammatory granuloma is seen. Under the light microscope, congestion and edema were alleviated, and inflammatory cell infiltration was alleviated.
  • Lymphocytes and plasma cells were dominant, neutrophils were rare, and eosinophils were seen in individual colon tissues, and the inflammatory cell invasion level became shallow.
  • Concentrated in the submucosa as shown in Figure 1 QCWZD high, medium and low doses of TNBS-induced colonic pathology in rats (X 40) (Note: A-blank group, B-model group, C-SASP group, D -QCWZD high dose group, E-QCWZD medium dose group, F-QCWZD low dose group).
  • the colon histopathology score of the model group was significantly higher than that of the blank group (0.05).
  • the colon histopathology scores of the various dose groups of the present invention were significantly lower than the model group ( ⁇ 0.), wherein the QCWZD high and QCWZD medium dose group inflammation of the present invention.
  • the degree of inflammatory infiltration (II) was significantly lower than that of the model group (P ⁇ 0.05), as shown in Table 3.
  • Blank group 5 0.00 ⁇ 0 ⁇ 00 1.11 ⁇ 1.
  • Model group 6 1.33 ⁇ 0 ⁇ 82 7.33 ⁇ 0 ⁇ 82 e
  • QCWZD medium agent i group 6 0.27 ⁇ 0 ⁇ 46 g 3.17 ⁇ L 40 g
  • the levels of serum IL-6 and TNF- ⁇ in the model group were significantly higher than those in the blank group (3 ⁇ 4 05).
  • the levels of serum IL-6 and TNF- ⁇ in the SASP group were significantly lower than those in the model group (P ⁇ 0.05).
  • the TNF- ⁇ level of the QCWZD high and QCWZD middle dose groups in the present invention was significantly lower than that in the model group ( ⁇ 0.05), and there was no significant difference between the blank group and the blank group (0.05).
  • the QCWZD low-dose group had a significant decrease in IL-6 compared with the model group (P ⁇ 0.05), which was significantly different from the blank group. ⁇ ⁇ > 0 ⁇ 05), as shown in Table 4.
  • the traditional Chinese medicine composition of the present invention has a protective effect on the intestinal mucosa of TNBS-induced colitis rats, and can effectively improve the invasion of colonic tissue cells;
  • the traditional Chinese medicine composition of the present invention can exert an anti-inflammatory effect on TNBS-induced colitis rats by down-regulating serum IL-6 and TNF- ⁇ levels.
  • Figure 1 is a diagram showing the colon pathology (X40) of a TNS-induced colitis rat treated with a traditional Chinese medicine composition prepared in Example 1 of the present invention.
  • Rhizoma Coptidis 7g Gun Ginger llg, Sophora flavescens 7g, Panax notoginseng 8g, Qinglan 4g, Muxiang 8g, Mangki charcoal 7g and Zhigancao 5g.
  • the traditional Chinese medicine composition is prepared into granules according to the following steps: (a) According to the selected parts by weight, take the mixture of berberine, gun ginger, Kushen, Sanqi, Qinglan, Muxiang, Dijiao and Licorice, add water and cook twice, add 570ml of water for the first time, decoction. 1.5 hours, add 456ml of water for the second time, decoct for 1 hour, filter, and combine the filtrate, let stand overnight, and concentrate the supernatant to 60 ° C with a relative density of 1.2-1.25;
  • the traditional Chinese medicine composition is prepared into granules according to the following steps:
  • Huanglian 9g gun ginger 9g, Sophora flavescens 9g, Sanqi 6g, Qinglan 9g, Muxiang 6g, Dijiao charcoal 9 3 ⁇ 4 ⁇ licorice 3g.
  • the traditional Chinese medicine composition is prepared into a pill according to the following steps:
  • Huanglian 8g gun ginger 10g, Sophora flavescens 8g, Sanqi 7g, Qinglan 5g, Muxiang 7g, Mangki charcoal 10g and Zhigancao 4g.
  • the traditional Chinese medicine composition is prepared as a suppository according to the following steps:
  • Coptis 7g gun ginger l lg, Sophora flavescens 7g, Panax notoginseng 8g, Qinglan 4g, Muxiang 8g, Mangki charcoal 7g and Zhigancao 5g.
  • the traditional Chinese medicine composition is prepared into granules according to the following steps:
  • Example 6 Capsule dosage form
  • the traditional Chinese medicine composition for treating ulcerative colitis of the present embodiment has the following formula: berberine l lg, gun ginger 7 g, matrine 7 g, panax notoginseng 8 g, barley l lg, woody 4 g, mantle charcoal l lg and licorice Lg.
  • the traditional Chinese medicine composition is prepared into a capsule according to the following steps:
  • Huanglian 9g gun ginger 9g, Sophora flavescens 9g, Sanqi 6g, Qinglan 9g, woody 6g, mantle charcoal 9g and Zhigancao 3g.
  • the traditional Chinese medicine composition is added into a pharmaceutically acceptable excipient according to a conventional process to prepare a pill.
  • Example 8 Suppository Formula The traditional Chinese medicine composition for treating ulcerative colitis of the present embodiment has the following formula:
  • Huanglian 8g gun ginger 10g, Sophora flavescens 8g, Sanqi 7g, Qinglan 5g, Muxiang 7g, Mangki charcoal 10g and Zhigancao 4g.
  • the traditional Chinese medicine composition is added to a pharmaceutically acceptable excipient according to a conventional process to prepare a suppository.
  • the traditional Chinese medicine composition is added into a pharmaceutically acceptable excipient according to a conventional process to prepare a granule.
  • Example 10 capsule The traditional Chinese medicine composition for treating ulcerative colitis of the present embodiment has the following formula: berberine 9g, gun ginger 9g, matrine 9g, panax notoginseng 6g, barley 8g, woody 5g, mantle charcoal 7g and licorice root 3g.
  • the traditional Chinese medicine composition is prepared into a capsule by adding a pharmaceutically acceptable auxiliary material according to a conventional process.
  • Huanglian 8g gun ginger 7g, Sophora flavescens 7g, Sanqi 6g, Qinglan l lg, woody 4g, mantle charcoal l lg and Zhigancao 4g.
  • the traditional Chinese medicine composition is added into a pharmaceutically acceptable excipient according to a conventional process to prepare a pill.
  • the traditional Chinese medicine composition is added to a pharmaceutically acceptable excipient according to a conventional process to prepare a suppository.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

一种治疗溃疡性结肠炎的中药组合物,所述组合物的原料药组成为:黄连7-11重量份、炮姜7-11重量份、苦参7-11重量份、三七4-8重量份、青黛4-11重量份、木香4-8重量份、地榆炭7-11重量份和炙甘草1-5重量份。所述中药组合物治疗溃疡性结肠炎效果好,且复发率低,副作用不明显,同时具有清利肠道,温中健脾,平调寒热,化瘀止血的效果,减轻疾病痛苦,提高生活质量,延长生存时间。

Description

一种用于治疗溃疡性结肠炎的中药组合物及其制备方法 技术领域 本发明属于中药制剂领域, 具体涉及一种治疗溃疡性结肠炎的中药组 合物及其制备方法。
背景技术
溃疡性结肠炎 (Ulcerative col itis, UC) 是一种病因尚不十分清楚的 结肠和直肠慢性非特异性炎症性疾病, 病变局限于大肠黏膜及黏膜下层。 病变多位于乙状结肠和直肠, 也可延伸至降结肠, 甚至整个结肠, 病程漫 长, 常反复发作, 可发生在任何年龄, 多见于书 20-40 岁, 男女发病率无明 显差别, 是消化内科的疾病, 中医属 "肠擗"、 "痢疾"等范畴。 溃疡性结 肠炎的临床表现可有许多形式, 粘液脓血便是本病活动期的重要表现, 其 他症状有腹痛、 恶心、 呕吐、 体重减轻、 里急后重等, 有时会伴发外周关 节炎, 巩膜外层炎, 口腔溃疡和皮肤病变等肠外表现, 中、 重型患者活动 期则会有发热、 贫血等全身表现。 在大多数病人中本病表现为慢性、 低恶 性, 在少数病人(约占 15%) 中呈急性起病, 偶见急性暴发起病。 这些病人 表现为频繁血性粪便, 可多达 30 次 /天, 和高热、 腹痛。 同时, 体征与病 期和临床表现直接相关, 病人往往有体重减轻和面色苍白, 在疾病活动期 腹部检查时结肠部位常有触痛, 可能有急腹症征象伴发热和肠鸣音减少, 在急性发作或暴发型病例尤为明显, 中毒性巨结肠时可有腹胀、 发热和急 腹症征象。 由于频繁腹泻, 肛周皮肤可有擦伤、 剥脱。 还可发生肛周炎症 如肛裂或肛瘘, 虽然后者在 Crohn' s病中更为常见, 直肠指检感疼痛, 皮 肤、 黏膜、 舌、 关节和眼部的检查极为重要。 近 20年来我国炎症性肠病, 特别是溃疡性结肠炎的发病率、 患病率呈逐渐增加趋势, 粗略推测 UC患病 率约为 11. 6/10万。
在现有技术中, 氨基水杨酸类药物是目前临床上常用的治疗轻中度溃 疡性结肠炎的药物, 包括水杨酸柳氮磺胺吡啶 (SASP )、 5-氨基水杨酸 ( 5-ASA) , 等, 其不良反应较多, 如恶心、 呕吐、 溶血等, 且对部分患者 疗效不佳。 糖皮质激素类药物如波尼松龙、 地塞米松、 氢化可的松等, 仅 对短期缓解症状有较好的效果, 部分药物存在生物利用度较低, 肠道遗留 多等缺陷, 且长期服用激素类药物会加重或诱发感染、 出现与累积量有关 的迟发、 阴袭性不良反应等。 现有技术中关于中药治疗溃疡性结肠炎的很 多, 例如 《中药配方颗粒辨证治疗溃疡性结肠炎 43例疗效观察》 中介绍了 中医治疗一般按辨证分为湿热内蕴型, 多为发病初期或急性复发期, 具有 便中挟脓带血, 气味秽臭, 里急后重, 肛门灼热等症状, 宜清热利湿, 调 和气息, 以白头翁汤为主方; 气滞血瘀型为慢性复发型的病人, 具有泄泻 不爽, 腹痛有定处拒按, 大便带有粘液或脓血, 面色晦暗, 嗳气少食等症 状, 用柴胡疏肝散合失笑散; 肝郁脾虚型为慢性复发型或持续型患者, 具 有腹中肠鸣, 腹痛腹泻, 泄后痛减, 胸闷胁胀等症状, 宜舒肝健脾, 行气 和胃, 用痛泻要方合参苓白术散; 脾胃虚弱型, 慢性持续型患者, 具有大 便时溏时泻, 挟有粘液或水谷不化, 面色蒌黄, 肢倦无力, 舌淡苔白, 脉 细弱等症状, 宜健脾益气, 和胃利湿, 以参苓白术散为主方; 脾肾阳虚型 为慢性持续型患者, 具有五更泄泻, 腹泻晨起为甚, 午后则轻大便稀薄, 腹中隐痛等症状, 宜温补脾肾, 涩肠止泻, 用四神丸合附子理中丸为主加 减; 阴血亏虚型, 为慢性持续型患者, 具有大便溏薄, 腹中隐痛, 午后潮 热, 神疲乏力, 舌红少苔, 宜养阴补血, 益气固肠, 用参苓白术散合沙参 麦冬汤为主。 但是现有的中药作用环节仍旧不清楚, 辨证分型不统一, 且 在现有公开的文献中疗效差异大。
发明内容
为此, 本发明所要解决的技术问题在于现有技术中的药物治疗溃疡性 结肠炎的效果不佳, 复发率高, 副作用明显, 进而提供一种治疗溃疡性结 肠炎效果好、 且复发率低以及副作用不明显的中药组合物及其制备方法。
为解决上述技术问题, 本发明提供了一种用于治疗溃疡性结肠炎的中 药组合物, 所述组合物的原料药组成为: 黄连 7-11重量份、 炮姜 7-11重 量份、 苦参 7-11重量份、 三七 4-8重量份、 青黛 4-11重量份、 木香 4-8 重量份、 地榆炭 7-11重量份和炙甘草 1-5重量份。 所述的用于治疗溃疡性结肠炎的中药组合物, 所述组合物的原料药组 成为: 黄连 9重量份、 炮姜 9重量份、 苦参 9重量份、 三七 6重量份、 青 黛 9重量份、 木香 6重量份、 地榆炭 9重量份和炙甘草 3重量份; 或
黄连 7重量份、 炮姜 11重量份、 苦参 7重量份、 三七 8重量份、 青黛 4重量份、 木香 8重量份、 地榆炭 7重量份和炙甘草 5重量份; 或
黄连 11重量份、 炮姜 7重量份、 苦参 7重量份、 三七 8重量份、 青黛 11重量份、 木香 4重量份、 地榆炭 11重量份和炙甘草 1重量份; 或
黄连 8重量份、 炮姜 10重量份、 苦参 8重量份、 三七 7重量份、 青黛 5重量份、 木香 7重量份、 地榆炭 10重量份和炙甘草 4重量份; 或
黄连 10重量份、 炮姜 8重量份、 苦参 10重量份、 三七 5重量份、 青 黛 10重量份、 木香 5重量份、 地榆炭 8重量份和炙甘草 2重量份; 或
黄连 9重量份、 炮姜 9重量份、 苦参 9重量份、 三七 6重量份、 青黛 8 重量份、 木香 5重量份、 地榆炭 7重量份和炙甘草 3重量份; 或
黄连 8重量份、 炮姜 7重量份、 苦参 7重量份、 三七 6重量份、 青黛 11重量份、 木香 4重量份、 地榆炭 11重量份和炙甘草 4重量份; 或
黄连 11重量份、 炮姜 11重量份、 苦参 11重量份、 三七 8重量份、 青 黛 4重量份、 木香 4重量份、 地榆炭 11重量份和炙甘草 5重量份。 所述的用于治疗溃疡性结肠炎的中药组合物, 所述组合物按照常规工 艺加入常规辅料制成临床上可接受的颗粒剂、 胶囊、 丸剂、 栓剂等剂型。
一种制备上述用于治疗溃疡性结肠炎的中药组合物的方法, 该方法包 括如下步骤:
(a)按照选定的重量份数取黄连、 炮姜、 苦参、 三七、 青黛、 木香、 地 榆炭和炙甘草, 分别粉碎成细粉后混合或混合后粉碎成细粉, 过 100-150 目筛备用;
(b)取上述细粉, 加入常规辅料按照常规工艺制成临床上可接受的颗粒 剂、 胶囊、 丸剂、 栓剂。
还包括另一种制备上述用于治疗溃疡性结肠炎的中药组合物的方法, 该方法包括如下步骤:
(a)按照选定重量份数取黄连、 炮姜、 苦参、 三七、 青黛、 木香、 地榆 炭和炙甘草混合, 加水煎煮二次, 第一次加 8-12 倍药物重量的水, 煎煮 1.5-2.5小时, 第二次加 6-10倍量水, 煎煮 1-2小时, 滤过, 合并滤液, 静 置过夜, 取上清液浓缩至 60°C相对密度为 1.2-1.25的浸膏;
(b)取所述浸膏, 加入常规辅料按照常规工艺制成临床上可接受的颗粒 剂、 胶囊、 丸剂、 栓剂。
进一步的, 该方法包括如下步骤:
(a)按照选定重量份数取黄连、 炮姜、 苦参、 三七、 青黛、 木香、 地榆 炭和炙甘草混合, 加水煎煮二次, 第一次加 10倍药物重量的水, 煎煮 2小 时, 第二次加 8倍量水, 煎煮 1.5小时, 滤过, 合并滤液, 静置过夜, 取上 清液浓缩至 60 °C相对密度为 1.2-1.25的浸膏;
(b)取所述浸膏, 加入常规辅料按照常规工艺制成临床上可接受的颗粒 剂、 胶囊、 丸剂、 栓剂。
还包括另一种制备上述用于治疗溃疡性结肠炎的中药组合物的方法, 该方法包括如下步骤:
按照选定重量份数取黄连、 炮姜、 苦参、 三七、 青黛、 木香、 地榆炭 和炙甘草混合粉碎成粗粉, 加 4-12倍药物重量的 55-75%乙醇, 浸渍 12-48 小时后, 对药液加热保持药液温度为 30°C〜40°C, 强制循环 3-4小时, 过 滤, 得醇提液, 加入常规辅料, 按照常规工艺制成临床上可接受的颗粒剂、 胶囊、 丸剂、 栓剂。 进一步的, 该方法包括如下步骤:
按照选定重量份数取黄连、 炮姜、 苦参、 三七、 青黛、 木香、 地榆炭 和炙甘草混合粉碎成粗粉, 加 8倍药物重量的 60%乙醇, 浸渍 30小时后, 对药液加热保持药液温度为 35°C, 强制循环 3. 5小时, 过滤, 得醇提液, 加入常规辅料, 按照常规工艺制成临床上可接受的颗粒剂、 胶囊、 丸剂、 栓剂。
本发明还公开了一种由上述的制备方法制备得到的用于治疗溃疡性结 肠炎的中药组合物, 以及由上述的中药组合物用于制备治疗溃疡性结肠炎 药物的应用。
申请人经过长期大量临床观察和实践, 认为溃疡性结肠炎患者的临床 以腹泻, 粘液脓血便, 腹痛, 里急后重为主症, 病机是脾虚为本, 肠道湿 热为标, 病机关键为寒热错杂, 湿热瘀阻, 治疗当清肠温中, 化瘀止血, 平调寒热, 制定本发明所述的中药组合物, 用于治疗临床溃疡性结肠炎取 得很好的效果; 本发明中药组合物由黄连, 炮姜, 苦参, 三七, 青黛, 木 香、 地榆炭和炙甘草组成, 方中黄连、 苦参、 青黛、 地榆炭苦寒入血分, 可清肠止血; 炮姜性温既可温脾止泻, 又可制黄连等诸药之苦寒, 平调寒 热; 三七化瘀止血, 木香条畅气机, 诸药合用能取到清利肠道湿热, 温中 健脾, 平调寒热, 化瘀止血的功效, 从而达到减轻疾病痛苦, 提高生活质 量, 延长生存时间的目的。
本发明的上述技术方案相比现有技术具有以下优点:
( 1 ) 本发明所述的用于治疗溃疡性结肠炎的中药组合物治疗效果好, 具有清利肠道湿热, 温中健脾, 平调寒热, 化瘀止血的效果, 从而达到减 轻疾病痛苦, 提高生活质量, 延长生存时间的目的;
( 2 )本发明所述的用于治疗溃疡性结肠炎的中药组合物与现有的药物 柳氮磺吡啶肠溶片相比,二者疾病活动指数(desease activity index, DAI ) 水平无明显差异; 对于大鼠结肠粘膜损伤指数, 使用本发明的中药组合物 的实验性结肠炎大鼠的结肠与周围组织粘连较轻, 结肠表面未见红褐色炎 症性伪膜, 充血、 水肿减轻, 与现有的药物柳氮磺吡啶肠溶片的结肠粘膜 损伤指数 ( conlonic mucosa damage index, CMDI ) 水平无明显差异; 本发 明各个剂量组结肠组织病理学评分均明显低于模型组 P〈0. 05 , 其中本 发明 QCWZD高、 QCWZD中剂量组炎细胞侵润的程度明显低于模型组; 大鼠血 清 IL-6、 TNF- α水平均较模型组有明显下降 P〈0. 05),且与空白组水平无 明显差异;
( 3 ) 本发明所述的用于治疗溃疡性结肠炎的中药组合物的制备方法, 通过该方法获得了临床上可接受的颗粒剂、 胶囊、 丸剂、 栓剂等剂型的中 药组合物, 更加便于服用、 保存、 稳定性好、 安全性高。
下述实验例用以证明本发明所述药物组合物的技术效果。
实验例 1
以下通过基础试验例更好地说明本发明在治疗溃疡性结肠炎方面的用 途。 本发明的中药组合物与对照组比较, 证明本发明的中药组合物治疗溃 疡性结肠炎的效果显著。
1.实验材料
实验动物:健康 SD大鼠, 雄性 35只,体重 200 ± 20g, 级别 SPF级。 实验药物: 试验组的药物为本实施例 1中制备的中药组合物, 每次给药 剂量按鼠体重为生药量 1200mg/kg、生药量 600mg/kg、生药量 300mg/kg分成 QCWZD高、 QCWZD中、 QCWZD低剂量试验组; 对照组为 SASP组, 即药 物为柳氮磺吡啶肠溶片, 每次给药剂量按体重为 400mg/kg。
给药方法: 灌胃。
2.实验方法及结果:
2. 1试验方法
取体重 200 ± 20g, 健康 SD大鼠 35只, 雄性, 随机分为六组: 空白组为 健康的 SD大鼠, 灌入 0. 6ml的去离子水; 其余各组依照现有文献中的造模方 法进行造模, 即为 TNBS/乙醇灌肠诱导的实验性结肠炎大鼠模型: 造模前 SD 大鼠禁食不禁水 24h, 10%水合氯醛(0. 3ml/100g)腹腔注射麻醉大鼠, 将乳 胶软管用液体石蜡润滑后由肛门缓慢轻插入直肠约 8cm, 一次性缓慢推注含 33. 3%乙醇的 TNBS溶液 ( 100mg/kg ) 0. 6ml , lmin之内完成, 保持仰卧位臀 部向上 15min, 自然苏醒后放回笼中, 常规词养, 3天后随即取 5只大鼠处死 后分离查看结肠组织, 均有明显的结肠粘膜损伤, 提示造模成功。
给药方法: 空白组和模型组均给 lOml/kg鼠体重的生理盐水; 对照组, 给药剂量为 400mg/kg鼠体重; QCWZD高、 中、 低剂量组为本发明实施例 1制 备的中药组合物按给药剂量分为高、 中、 低量组, 每次给药剂量分别为生 药量 1200mg/kg鼠体重、 生药量 600mg/kg鼠体重、 生药量 300mg/kg鼠体重。 各给药组均灌胃给药, 每日 1次, 连用 10天。
2. 2试验结果
2. 2. 1对 TNBS诱导的实验性结肠炎大鼠的疗效的观察
2. 2. 1. 1对 TNBS诱导的实验性结肠炎大鼠 DAI的影响
造模后第 2天,模型组大鼠出现腹泻, 为黄色稀便、半稀便甚至血便, 此时大鼠毛色失去光泽, 活动性差, 反应迟缓、 懒动, 至第 3天 DAI达到 最大。 用药 4天后 (DAY7)各用药组大鼠精神好转, 毛色渐有光泽, 食欲增 加,活动逐渐增多,大便逐渐正常, DAI明显下降 Ο ),用药 5天 (DAY8) 到用药 10天 (DAY13) DAI的恢复较为缓慢,各组 DAI程度 DAY13与 DAY7无明 显差别 ί Ρ>0· 05。空白组大鼠则无上述精神、活动、毛色等变化, 如表 1。 药物干预 10天后, 模型组 DAI仍明显高于空白组 (P<0. 05), SASP组及本 发明各剂量组均较模型组有明显的下降 (Ρ〈0. 05), 本发明 QCWZD高中低剂 量组 DAI水平较柳氮磺吡啶组 (salazosulfapyridine , SASP ) 组无明显差 异 P〉0. 05) , 如表 2。
表 1. DAI日变化表 g DAY1 DAY3 DAY7 DAY 13 空白组 0.00 ±0· 00 0.00 ±0· 00 0.00 ±0· 00 0.00 ±0· 00 模型组 0.00 ±0· 00 1.53±0· 39 0.90 ±0· 75a 0.95 ±0· 49ad
SASP组 0.00 ±0· 00 1.83±0· 39 0.67 ±0· 54a 0.42 ±0.35ad
QCWZD高剂 1:组 0.00 ±0· 00 1.37±0· 56 0.57±0· 32a 0.50 ±0.25ad
QCWZD中剂 1:组 0.00 ±0· 00 2.10±0· 47 0.53±0· 61a 0.45 ±0.47ad
QCWZD低剂 1:组 0.00 ±0· 00 2.13±0· 45 0.47 ±0.39a 0.46 ±0.31ad 注: Ρ〈0.05, hP>0.05与 DAY3比较; CP<0.05, &Ρ〉0· 05与 DAY7比较。
2.2.1.2大鼠结肠粘膜损伤指数
模型组肉眼可见结肠黏膜糜烂重, 溃疡较深且面积较大, 溃疡处有明 显肠内容物嵌入, 不易冲洗; 可见明显水肿, 充血, 结肠表面覆盖有红褐 色炎症性伪膜;结肠病变处肠腔扩张变形;病变结肠与周围组织粘连明显, 不易分离。 各用药组结肠与周围组织粘连较轻, 结肠表面未见红褐色炎症 性伪膜, 充血、 水肿减轻, 溃疡呈愈合性表现。 用药 10天后, 模型组结肠 粘膜损伤指数 (colonic mucosa damage index, CMDI) 仍明显高于空白组 {P<0.05), SASP组及本发明 QCWZD中剂量组较模型组均明显下降 ° ¾ 05), 此二组 CMDI水平无明显差异 ίΡ>0.05 , 如表 2。
表 2.药物对 TNBS诱导的结肠炎大鼠 CMDI、 DAI的影响 g n CMDI DAI 空白组 5 0.20 ±0.45 0.07±0· 15 模型组 6 3.33±0· 82e 0.95 ±0· 49e
SASP组 6 2.44±0· 73g 0.48 ±0.35g
QCWZD高剂 1:组 6 2.50±1· 22 0.50 ±0.25
QCWZD中剂 1:组 6 2.25 ±0.89gh 0.45 ±0.27gh
QCWZD低剂 1:组 6 3.00 ±0· 00 0.46 ±0.31 注: eP〈0.05, fP>0. 与空白组比较; gP<0. 与模型组比较; P>0.05与 SASP组比较。
2.2.1.3大鼠结肠 HS 模型组光镜下可见黏膜充血、 水肿, 大量炎性细胞浸润,以淋巴细胞及 中性粒细胞侵润为主, 病变深度达粘膜下层、 肌层甚至浆膜层; 杯状细胞 明显减少, 溃疡周围部分腺体扩张,腺体排列紊乱, 腺上皮细胞轻度增生, 部分伴有腺体非典型增生,可见炎症性肉芽肿。各用药组光镜下可见充血、 水肿减轻, 炎细胞侵润减轻, 以淋巴细胞、浆细胞为主, 中性粒细胞少见, 个别结肠组织可见嗜酸性粒细胞, 炎细胞侵润层次变浅, 集中在粘膜下层, 如图 1的 QCWZD高、中、低剂量治疗 TNBS诱导的结肠炎大鼠结肠病理图( X 40) (注: A-空白组, B-模型组, C-SASP组, D-QCWZD高剂量组, E-QCWZD 中剂量组, F-QCWZD低剂量组) 。模型组结肠组织病理学评分明显高于空白 组 ίΡ〈0.05 ,本发明各个剂量组结肠组织病理学评分均明显低于模型组 (Ρ<0. ),其中本发明 QCWZD高、 QCWZD中剂量组炎细胞侵润(Inflammatory infiltration, II) 的程度明显低于模型组 P〈0.05、 , 如表 3。
表 3.药物对 TNBS诱导的结肠炎大鼠 HS的影响
II HS
空白组 5 0.00 ±0· 00 1.11±1. , 05 模型组 6 1.33±0· 82 7.33±0· 82e
SASP组 6 1.17±1· 03 5.92±2. , 15
QCWZD高剂 i:组 6 0.33±0· 71g 5.00±L 50g
QCWZD中剂 i:组 6 0.27 ±0· 46g 3.17±L 40g
QCWZD低剂 i:组 6 0.93 ±0.96 5.20 + 2. 40g 注: eP<0.05, fP>0. 与空白组比较; eP<0. 与模型组比较。
2.2.2大鼠血清炎症因子 TNF- α、 IL- 6的影响
模型组结肠炎大鼠血清 IL-6、TNF- α水平均明显高于空白组( ¾ 05); SASP组大鼠血清 IL-6、 TNF- α水平均较模型组有明显下降 P〈0.05 ,且 与空白组水平无明显差异( 3^.05);本发明 QCWZD高、 QCWZD中剂量组 TNF- α水平均较模型组有明显下降 Ρ〈0.05), 与空白组无明显差异 Ρ〉0.05); QCWZD低剂量组 IL-6较模型组有明显下降 P<0.05), 与空白组与明显差异 ίΡ〉0· 05), 如表 4。
表 4.药物对 TNBS诱导的结肠炎大鼠血清 IL-6、 TNF- α的影响 g n IL-6 TNF-α 空白组 5 112.01±6· 53 63.92±7· 53 模型组 6 162.52±32· 06e 78.98 ±1.78e
SASP组 6 123.90±30· llfg 64.63 ±8· 90fg
QCWZD高剂 i t组 6 135.16±12· 75 67.53 ±4· 59fg
QCWZD中剂 i t组 6 142.15±7· 09 67.79 ±6.48fg
QCWZD低剂 i t组 6 114.75 ±18.43fg 70.20±7.82 注: β ,^β 与空白组比较; ftft^与模型组比较。 3.结论
(1) 本发明的中药组合物对 TNBS诱导的结肠炎大鼠肠粘膜有保护作 用, 且能有效改善结肠组织炎细胞侵润;
(2) 本发明的中药组合物能通过下调血清 IL-6、 TNF-α水平对 TNBS 诱导的结肠炎大鼠起到抗炎的作用。
附图说明
为了使本发明的内容更容易被清楚的理解, 下面根据本发明的具体实 施例并结合附图, 对本发明作进一步详细的说明, 其中
图 1是本发明实施例 1制备的中药组合物治疗 TNBS诱导的结肠炎大鼠 结肠病理图 (X40)。
具体实施方式
实施例 1 颗粒剂型
本实施例的治疗溃疡性结肠炎的中药组合物, 其配方如下:
黄连 7g、 炮姜 llg、 苦参 7g、 三七 8g、 青黛 4g、 木香 8g、 地榆炭 7g 和炙甘草 5g。 所述中药组合物按照以下步骤制备成颗粒剂: (a) 按照选定重量份数取黄连、 炮姜、 苦参、 三七、 青黛、 木香、 地 榆炭和炙甘草混合,加水煎煮二次,第一次加 570ml的水,煎煮 1.5小时, 第二次加 456ml的水, 煎煮 1小时, 滤过, 合并滤液, 静置过夜, 取上清 液浓缩至 60 °C相对密度为 1.2-1.25的浸膏;
(b) 取所述浸膏,按照常规工艺加入药剂学上的常规辅料制成临床上可 接受的颗粒剂。
实施例 2 胶囊剂型
本实施例的治疗溃疡性结肠炎的中药组合物, 其配方如下:
黄连 l lg、炮姜 7g、苦参 7g、三七 8g、青黛 l lg、木香 4g、地榆炭 11 和炙甘草 lg。
所述中药组合物按照以下步骤制备成颗粒剂:
(a)按照上述选定重量的原料药取黄连、 炮姜、 苦参、 三七、 青黛、 ^ 香、 地榆炭和炙甘草混合, 加水煎煮二次, 第一次加 12倍药物重量的水 煎煮 2小时,第二次加 10倍药物重量水,煎煮 1.5小时,滤过,合并滤液, 争置过夜, 取上清液浓缩至 60°C相对密度为 1.2-1.25的浸膏;
(b) 取所述浸膏, 按照常规工艺加入药剂学上的常规辅料制成临床」 "接受的胶囊剂。
实施例 3 丸剂型
本实施例的治疗溃疡性结肠炎的中药组合物, 其配方如下:
黄连 9g、 炮姜 9g、 苦参 9g、 三七 6g、 青黛 9g、 木香 6g、 地榆炭 9 ¾炙甘草 3g。
所述中药组合物按照以下步骤制备成丸剂:
(a)按照上述选定重量的原料药, 取黄连、 炮姜、 苦参、 三七、 青黛 ^香、地榆炭和炙甘草混合, 加水煎煮二次,第一次加 8倍药物重量的水, H煮 1.5小时, 第二次加 6倍药物重量水, 煎煮 2小时, 滤过, 合并滤液 静置过夜, 取上清液浓缩至 60°C相对密度为 1.2-1.25的浸膏;
(b) 取所述浸膏, 按照常规工艺加入药剂学上的常规辅料, 制丸, 干 燥, 选丸, 包装, 制成临床上可接受的丸剂。
实施例 4 栓剂型
本实施例的治疗溃疡性结肠炎的中药组合物, 其配方如下:
黄连 8g、 炮姜 10g、 苦参 8g、 三七 7g、 青黛 5g、 木香 7g、 地榆炭 10g 和炙甘草 4g。
所述中药组合物按照以下步骤制备成栓剂:
(a)按照上述选定重量的原料药, 取黄连、 炮姜、 苦参、 三七、 青黛、 木香、地榆炭和炙甘草混合,加水煎煮二次,第一次加 10倍药物重量的水, 煎煮 2.5小时,第二次加 8倍药物重量水,煎煮 1.5小时,滤过,合并滤液, 静置过夜, 取上清液浓缩至 60°C相对密度为 1.2-1.25的浸膏;
(b) 取所述浸膏, 按照常规工艺加入药剂学上的常规辅料制成临床上 可接受的栓剂。
实施例 5颗粒剂型
本实施例的治疗溃疡性结肠炎的中药组合物, 其配方如下:
黄连 7g、 炮姜 l lg、 苦参 7g、 三七 8g、 青黛 4g、 木香 8g、 地榆炭 7g 和炙甘草 5g。
所述中药组合物按照以下步骤制备成颗粒剂:
(a)按照选定的重量份数取黄连、 炮姜、 苦参、 三七、 青黛、 木香、 地 榆炭和炙甘草, 分别粉碎成细粉后混合或混合后粉碎成细粉, 过 120 目筛 备用;
(b)取上述细粉, 加入常规辅料按照常规工艺制成临床上可接受的颗粒 剂。
实施例 6 胶囊剂型 本实施例的治疗溃疡性结肠炎的中药组合物, 其配方如下: 黄连 l lg、炮姜 7g、苦参 7g、三七 8g、青黛 l lg、木香 4g、地榆炭 l lg 和炙甘草 lg。
所述中药组合物按照以下步骤制备成胶囊剂:
按照选定重量份数取黄连、 炮姜、 苦参、 三七、 青黛、 木香、 地榆炭 和炙甘草混合粉碎成粗粉, 加 360ml的 75%乙醇, 浸渍 12小时后, 对药液 加热保持药液温度为 30°C〜40°C, 强制循环 3. 5小时, 过滤, 得醇提液, 加入常规辅料, 按照常规工艺制成临床上可接受的胶囊剂。
实施例 7丸剂型
本实施例的治疗溃疡性结肠炎的中药组合物, 其配方如下:
黄连 9g、 炮姜 9g、 苦参 9g、 三七 6g、 青黛 9g、 木香 6g、 地榆炭 9g 和炙甘草 3g。
所述中药组合物按照常规工艺加入药学上常规辅料制成丸剂。
实施例 8 栓剂型 本实施例的治疗溃疡性结肠炎的中药组合物, 其配方如下:
黄连 8g、 炮姜 10g、 苦参 8g、 三七 7g、 青黛 5g、 木香 7g、 地榆炭 10g 和炙甘草 4g。
所述中药组合物按照常规工艺加入药学上常规辅料制成栓剂。
实施例 9颗粒剂
本实施例的治疗溃疡性结肠炎的中药组合物, 其配方如下:
黄连 10g、 炮姜 8g、 苦参 10g、 三七 5g、 青黛 10g、 木香 5g、 地榆炭
8g和炙甘草 2g。 所述中药组合物按照常规工艺加入药学上常规辅料制成颗粒剂。
实施例 10胶囊剂 本实施例的治疗治疗溃疡性结肠炎的中药组合物, 其配方如下: 黄连 9g、 炮姜 9g、 苦参 9g、 三七 6g、 青黛 8g、 木香 5g、 地榆炭 7g 和炙甘草 3g。
所述中药组合物按照常规工艺加入药学上常规辅料制成胶囊剂。
实施例 11丸剂
本实施例的治疗溃疡性结肠炎的中药组合物, 其配方如下:
黄连 8g、 炮姜 7g、 苦参 7g、 三七 6g、 青黛 l lg、 木香 4g、 地榆炭 l lg 和炙甘草 4g。
所述中药组合物按照常规工艺加入药学上常规辅料制成丸剂。
实施例 12栓剂
本实施例的治疗溃疡性结肠炎的中药组合物, 其配方如下:
黄连 l lg、 炮姜 l lg、 苦参 l lg、 三七 8g、 青黛 4g、 木香 4g、 地榆炭 l lg和炙甘草 5g。
所述中药组合物按照常规工艺加入药学上常规辅料制成栓剂。
显然, 上述实施例仅仅是为清楚地说明所作的举例, 而并非对实施方 式的限定。 对于所属领域的普通技术人员来说, 在上述说明的基础上还可 以做出其它不同形式的变化或变动。 这里无需也无法对所有的实施方式予 以穷举。 而由此所引伸出的显而易见的变化或变动仍处于本发明创造的保 护范围之中

Claims

权 利 要 求 书
1. 一种用于治疗溃疡性结肠炎的中药组合物, 其特征在于, 所述组合 物的原料药组成为:黄连 7-11重量份、炮姜 7-11重量份、苦参 7-11重量份、 三七 4-8重量份、 青黛 4-11重量份、 木香 4-8重量份、 地榆炭 7-11重量份 和炙甘草 1-5重量份。
2. 根据权利要求 1 所述用于治疗溃疡性结肠炎的中药组合物, 其特征 在于, 所述组合物的原料药组成为:
黄连 9重量份、 炮姜 9重量份、 苦参 9重量份、 三七 6重量份、 青黛 9 重量份、 木香 6重量份、 地榆炭 9重量份和炙甘草 3重量份; 或
黄连 7重量份、 炮姜 11重量份、 苦参 7重量份、 三七 8重量份、 青黛 4 重量份、 木香 8重量份、 地榆炭 7重量份和炙甘草 5重量份; 或
黄连 11重量份、 炮姜 7重量份、 苦参 7重量份、 三七 8重量份、 青黛 11 重量份、 木香 4重量份、 地榆炭 11重量份和炙甘草 1重量份; 或
黄连 8重量份、 炮姜 10重量份、 苦参 8重量份、 三七 7重量份、 青黛 5 重量份、 木香 7重量份、 地榆炭 10重量份和炙甘草 4重量份; 或
黄连 10重量份、 炮姜 8重量份、 苦参 10重量份、 三七 5重量份、 青黛 10重量份、 木香 5重量份、 地榆炭 8重量份和炙甘草 2重量份; 或
黄连 9重量份、 炮姜 9重量份、 苦参 9重量份、 三七 6重量份、 青黛 8 重量份、 木香 5重量份、 地榆炭 7重量份和炙甘草 3重量份; 或
黄连 8重量份、 炮姜 7重量份、 苦参 7重量份、 三七 6重量份、 青黛 11 重量份、 木香 4重量份、 地榆炭 11重量份和炙甘草 4重量份; 或
黄连 11重量份、 炮姜 11重量份、 苦参 11重量份、 三七 8重量份、 青黛 4重量份、 木香 4重量份、 地榆炭 11重量份和炙甘草 5重量份。
3. 根据权利要求 1或 2所述用于治疗溃疡性结肠炎的中药组合物, 其 特征在于, 所述中药组合物按照常规工艺加入常规辅料制成临床上可接受的 颗粒剂、 胶囊、 丸剂、 栓剂。
4. 一种制备如权利要求 1-3 任一所述用于治疗溃疡性结肠炎的中药组 合物的方法, 其特征在于, 该方法包括如下步骤:
(a)按照选定的重量份数取黄连、 炮姜、 苦参、 三七、 青黛、 木香、 地榆 炭和炙甘草,分别粉碎成细粉后混合或混合后粉碎成细粉,过 100-150目筛备 用;
(b)取上述细粉,加入常规辅料按照常规工艺制成临床上可接受的颗粒剂、 胶囊、 丸剂、 栓剂。
5. 一种制备如权利要求 1-3任一所述用于治疗溃疡性结肠炎的中药组合 物的方法, 其特征在于, 该方法包括如下步骤:
(a)按照选定重量份数取黄连、 炮姜、 苦参、 三七、 青黛、 木香、 地榆炭 和炙甘草混合, 加水煎煮二次, 第一次加 8-12倍药物重量的水, 煎煮 1.5-2.5 小时, 第二次加 6-10倍量水, 煎煮 1-2小时, 滤过, 合并滤液, 静置过夜, 取上清液浓缩至 60°C相对密度为 1.2-1.25的浸膏;
(b)取所述浸膏,加入常规辅料按照常规工艺制成临床上可接受的颗粒剂、 胶囊、 丸剂、 栓剂。
6. 根据权利要求 5所述的方法, 其特征在于, 该方法包括如下步骤:
(a)按照选定重量份数取黄连、 炮姜、 苦参、 三七、 青黛、 木香、 地榆炭 和炙甘草混合, 加水煎煮二次, 第一次加 10倍药物重量的水, 煎煮 2小时, 第二次加 8倍量水, 煎煮 1.5小时, 滤过, 合并滤液, 静置过夜, 取上清液浓 缩至 60 °C相对密度为 1.2-1.25的浸膏;
(b)取所述浸膏,加入常规辅料按照常规工艺制成临床上可接受的颗粒剂、 胶囊、 丸剂、 栓剂。
7. 一种制备如权利要求 1-3任一所述用于治疗溃疡性结肠炎的中药组合 物的方法, 其特征在于, 该方法包括如下步骤:
按照选定重量份数取黄连、 炮姜、 苦参、 三七、 青黛、 木香、 地榆炭和 炙甘草混合粉碎成粗粉, 加 4-12倍药物重量的 55-75%乙醇, 浸渍 12-48小时 后, 对药液加热保持药液温度为 30°C〜40°C, 强制循环 3-4小时, 过滤, 得 醇提液, 加入常规辅料, 按照常规工艺制成临床上可接受的颗粒剂、 胶囊、 丸剂、 栓剂。
8. 根据权利要求 7所述的方法, 其特征在于, 该方法包括如下步骤: 按照选定重量份数取黄连、 炮姜、 苦参、 三七、 青黛、 木香、 地榆炭和 炙甘草混合粉碎成粗粉, 加 8倍药物重量的 60%乙醇, 浸渍 30小时后, 对药 液加热保持药液温度为 35°C, 强制循环 3. 5小时, 过滤, 得醇提液, 加入常 规辅料, 按照常规工艺制成临床上可接受的颗粒剂、 胶囊、 丸剂、 栓剂。
9. 根据权利要求 4-9任一所述的方法制备得到的中药组合物。
10. 根据权利要求 1或 2或 3或 9所述的中药组合物用于制备治疗溃疡性 结肠炎药物的应用。
PCT/CN2013/088143 2013-11-29 2013-11-29 一种用于治疗溃疡性结肠炎的中药组合物及其制备方法 WO2015077977A1 (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/CN2013/088143 WO2015077977A1 (zh) 2013-11-29 2013-11-29 一种用于治疗溃疡性结肠炎的中药组合物及其制备方法
CN201380080916.6A CN105722521B (zh) 2013-11-29 2013-11-29 一种用于治疗溃疡性结肠炎的中药组合物及其制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2013/088143 WO2015077977A1 (zh) 2013-11-29 2013-11-29 一种用于治疗溃疡性结肠炎的中药组合物及其制备方法

Publications (1)

Publication Number Publication Date
WO2015077977A1 true WO2015077977A1 (zh) 2015-06-04

Family

ID=53198222

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2013/088143 WO2015077977A1 (zh) 2013-11-29 2013-11-29 一种用于治疗溃疡性结肠炎的中药组合物及其制备方法

Country Status (2)

Country Link
CN (1) CN105722521B (zh)
WO (1) WO2015077977A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018117659A1 (ko) * 2016-12-20 2018-06-28 서울대학교병원 청대 추출물 또는 이의 분획물을 유효성분으로 포함하는 염증성 장질환의 예방 또는 치료용 약학적 조성물
CN112190681A (zh) * 2020-10-29 2021-01-08 北京中医药大学东方医院 一种治疗溃疡性结肠炎的中药组合物及其制备方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107335029B (zh) * 2017-06-19 2021-01-19 南京海陵中药制药工艺技术研究有限公司 一种清肠温中颗粒的制备方法
CN112587643B (zh) * 2020-12-31 2022-03-01 南京中医药大学 一种抗肝纤维化中药复方组合物及其制备方法
CN115708862B (zh) * 2022-08-23 2023-12-19 李毅 一种治疗结肠炎的中药组合物
CN116211992B (zh) * 2023-03-22 2023-11-21 重庆市中医院 一种用于治疗溃疡性结肠炎诱发抑郁样行为的中药组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101912531A (zh) * 2010-08-13 2010-12-15 万秀玲 治疗结肠炎的中药灌肠汤剂
CN102698150A (zh) * 2012-05-07 2012-10-03 邓泽潭 一种治疗溃疡性结肠炎的内服中药组合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101912531A (zh) * 2010-08-13 2010-12-15 万秀玲 治疗结肠炎的中药灌肠汤剂
CN102698150A (zh) * 2012-05-07 2012-10-03 邓泽潭 一种治疗溃疡性结肠炎的内服中药组合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
SUN, MINGREN ET AL.: "Zh? ngx? yi jiéhé zhìliáo mànxìng tèyìxìng kuì yángxìng jiéchá ngyán 26lì liàoxi? o guánchá", JOURNAL OF HENAN MEDICAL UNIVERSITY, vol. 28, no. 4, 31 December 1993 (1993-12-31), pages 363 *
WU, SHENGGUANG: "kuì yángxìng jiéchángyán de Zh? ngy? yào zhìliáo jìnzh? n", THE JOURNAL OF MEDICAL THEORY AND PRACTICE, vol. 22, no. 1, 31 January 2009 (2009-01-31), pages 24 - 26 *
YANG, AIXUE ET AL.: "Zh? ngy? yào zhì liáo kuì yángxìng jiéchángyán línchuáng yánji? j ì nzh? n", JOURNAL OF EMERGENCY IN TRADITIONAL CHINESE MEDICINE, vol. 16, no. 6, 30 June 2007 (2007-06-30), pages 727 - 729 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018117659A1 (ko) * 2016-12-20 2018-06-28 서울대학교병원 청대 추출물 또는 이의 분획물을 유효성분으로 포함하는 염증성 장질환의 예방 또는 치료용 약학적 조성물
CN112190681A (zh) * 2020-10-29 2021-01-08 北京中医药大学东方医院 一种治疗溃疡性结肠炎的中药组合物及其制备方法

Also Published As

Publication number Publication date
CN105722521A (zh) 2016-06-29
CN105722521B (zh) 2019-06-28

Similar Documents

Publication Publication Date Title
WO2015077977A1 (zh) 一种用于治疗溃疡性结肠炎的中药组合物及其制备方法
CN104258151A (zh) 一种治疗肾盂肾炎的药物及制备方法
CN101708285A (zh) 中药治疗癌症的组合及其制备方法
CN104435454A (zh) 一种治疗慢性子宫内膜炎的药物及制备方法
CN103495072B (zh) 一种治疗支气管扩张病的中药组合物及其制备方法
CN107875211B (zh) 一种用于治疗溃疡性结肠炎的组合物及其制备方法和应用
CN105194460A (zh) 治疗风湿热型痛风发作急性期的中药制剂
CN103585449A (zh) 用于治疗偏头痛的中药组合物
CN112190681A (zh) 一种治疗溃疡性结肠炎的中药组合物及其制备方法
CN103285118A (zh) 蛇油烧伤膏
CN106177007A (zh) 一种用于治疗高危型hpv持续感染的宫颈疾病的中药栓剂及其制备方法
CN105194427A (zh) 一种治疗干眼症的中药组合物及其制备方法
CN103877384A (zh) 一种治疗直肠癌的中药制剂及制备方法
CN113925952B (zh) 一种中药组合物在制备防治消化道肿瘤药物中的应用
CN103028028B (zh) 一种治疗原发性肝癌的中药
CN114949131B (zh) 一种治疗克罗恩病的中药复方组合物及其制备方法
CN114984056B (zh) 一种治疗克罗恩病的天然产物提取物及其应用
CN103735999B (zh) 一种治疗痛风的中药制剂及制备方法
CN102406913A (zh) 一种治疗郁证的中药组合物
CN103705692B (zh) 一种治疗急性胃肠炎的中药制剂
CN102872210B (zh) 一种治疗荨麻疹的中药
CN102657727B (zh) 一种治疗结肠炎的药物及其制备方法
CN102091267A (zh) 一种治疗寻常型银屑病的药物及其制备方法
CN106619870A (zh) 治疗消化系统肿瘤的组合物及其制备方法
CN104288511A (zh) 一种治疗内痔出血的中药栓剂

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13898469

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13898469

Country of ref document: EP

Kind code of ref document: A1